Gliem, Martin
Birtel, Johannes
Herrmann, Philipp
Fimmers, Rolf
Berger, Moritz
Coch, Christoph
Wingen, Almut
Holz, Frank G.
Charbel Issa, Peter http://orcid.org/0000-0002-0351-6673
Funding for this research was provided by:
NIHR Oxford Biomedical Research Centre
Article History
Received: 8 August 2019
Revised: 13 November 2019
Accepted: 20 November 2019
First Online: 20 December 2019
Compliance with ethical standards
:
: Dr. Gliem is now employee and equity owner of F. Hoffmann-La Roche Ltd., Basel, Switzerland (since July 2019); he received financial support from Bayer AG and Heidelberg Engineering. Dr. Birtel received financial support from Heidelberg Engineering. Dr. Holz is consultant of Bayer AG, Heidelberg Engineering, and CenterVue. The Department of Ophthalmology, University Hospital of Bonn, Bonn, Germany, receives imaging devices from Heidelberg Engineering and CenterVue. Dr. Charbel Issa is consultant of Inozyme and received research support from Heidelberg Engineering. None of the authors has a proprietary interest in this study.
: All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the1964 Helsinki Declaration and its later amendments or comparable ethical standards. The study protocol and study documents were approved by the local ethics committee (Ethikkommission der Medizinischen Fakultät, Rheinische Friedrich-Wilhelms-Universität Bonn; Lfd. Nr. 056/15-AMG-ff). This article does not contain any studies with animals performed by any of the authors.
: Informed consent was obtained from all individual participants included in the study.